Short interest for Prime Medicine gives investors a sense of the degree to which investors are betting on the decline of Prime Medicine's stock. Short interest data is updated every two weeks.

Prime Medicine Stock (NASDAQ:PRME), Short Interest Report

First Trust Heitman Global Prime Real Estate ETF

Prime Medicine

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Image17

News

Pre-Market Outlook

Markets

Movers

APVO

ASPN

BFLY

CTMX

CVNA

DASH

ENVX

ETSY

FRSH

FSLY

IMCC

ONDS

PRME

QRVO

RELY

RENT

Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket

Intraday Update

ADXN

ALTM

ANVS

APLD

ATXI

CALT

CAUD

CGEM

CJJD

CLVR

CSSE

CVEO

CYCC

DAVE

DCPH

ENLV

FLGC

FTEL

FULT

HOPE

HTLF

IBRX

INHD

IONM

ISUN

KYTX

MESO

MPLN

MULN

NUZE

NWGL

OCGN

PAHC

SLNO

SOFI

SSKN

TCJH

TSLA

ZVSA

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Tesla logo

Trading Ideas

EXAI

PACB

PARA

ROKU

TELL

TNDM

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday

Prime Medicine Inc

Guidance

NDLS

Noodles & Company Reiterates 2024 Total Revenue Guidance $510M-$525M vs $518.08M Est.

Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $0.24 by 200 percent. This is a 214.29 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $76.299 million which beat the analyst consensus estimate of $76.276 million by 0.03 percent. This is a 4.47 percent decrease over sales of $79.870 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

AMPY

Amplify Energy Q1 2024 GAAP EPS $(0.24) Misses $0.24 Estimate, Sales $76.299M Beat $76.276M Estimate

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome Trial &nbsp;
Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety and Efficacy Findings
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3v4b4MqHBkv3k37ylvTGCiEAtio9pXgIZQAaeaEdlDJQ7dJsGt5OrAvRtCBsSwqFdBhWiAwUS3lM_zwni6zUVX6otKEPe0J-d2XVX3_p29IaMLeiQQZ_-aXgzL57tDqsPJg78hnZ4MLVbahFUmDh8-_VVeLYYbFEBgJCxhs_MwVbYfzbkZIboVCrEh-AfkqQ4nQZlgaN4UxibxWUppej8g==">Crinetics Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) today announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society's annual meeting, <a href="https://www.globenewswire.com/Tracker?data=VstDnKTuZhpW6aHWDR0orbsJQ0Fcjgo8hpsnDa1c7o94097CRwaMhcB6rt4dFKKFH4XbNrVdduMG1AEPyVPacfJoDeXePhs1yEAPma6IC0A=">ENDO 2024</a>, taking place June 1-4, 2024 in Boston, Massachusetts.
"This year's Endocrine Society meeting represents a major milestone for Crinetics as we present initial findings from two clinical studies of atumelnant&#x2A; (CRN04894), our investigational, once-daily oral ACTH receptor antagonist, in development for the treatment of people with classic congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, in addition to presentations featuring data from the acromegaly Phase 3 trials of our lead development candidate, paltusotine," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we work toward submission of the new drug application for paltusotine later this year, and as our second clinical asset, atumelnant, advances through development, we are very pleased with the progress toward our vision of building the premier endocrine-focused pharmaceutical company."
Two poster presentations will include clinical data for atumelnant, a novel, oral once-daily adrenocorticotropic hormone (ACTH) receptor antagonist in development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. One presentation will showcase initial safety and key biomarker efficacy findings in CAH, including rapid and profound reductions in androstenedione (A4) and 17-hydroxyprogesterone levels in participants, from the Phase 2 open label TouCAHn study. A second presentation includes data from a Phase 1b/2a open-label single center study of atumelnant in ACTH-dependent Cushing's syndrome and will feature the first evidence of rapid and sustained cortisol reductions in participants.
Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated. Additionally, data from the Phase 3 PATHFNDR-1 study of previously treated acromegaly patients who switched to paltusotine from an injected somatostatin receptor ligand, including a new analysis of patient-reported symptoms, will be presented as a poster presentation. Data from the PATHFNDR program will be featured in a <a href="https://www.globenewswire.com/Tracker?data=K19o8oRqat-NQgf4BKUQWBnhuNQ2KSvbnpuoNtt3mp1C621PaZJbY5MSrZCo9FTqw7tn6HcGhKq6kf3bw5nv5BQKG2micHhRsERk1XVOeiMJdkJAFgHEyN_IyUm9eZ7_37q4eDVaU_aqGFtpMp8iHOD2jpWo64rGnrkhV6qR5pZQ3tHC2SsBqclrsH3c9WiR2hZG5JQDzDOPaC3JjR42Fw==">Science and Innovation Theater</a> led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled "Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly." A third presentation from the paltusotine clinical program will be a poster showing long-term safety and efficacy updates from the Phase 2 ACROBAT Advance open-label extension study.
&#x2A;Proposed international nonproprietary name under review

Biotech

General

CRNX

Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024

Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.36 by 8.33 percent. The company reported quarterly sales of $215.492 million which missed the analyst consensus estimate of $220.551 million by 2.29 percent. This is a 13.35 percent increase over sales of $190.112 million the same period last year.

Kodiak Gas Services Q1 2024 GAAP EPS $0.39 Beats $0.36 Estimate, Sales $215.492M Miss $220.551M Estimate

UNIFI Sees Q4 2024 Net Sales $160M-$165M Vs $168.493M Est.

BIRD

Allbirds Sees Q2 Net Revenue Of $48M-$53M (Est $51.575M); Reiterates FY24 Outlook Of $190M-$210M (Est $198.25M)

LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 83.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $44.144 million which beat the analyst consensus estimate of $42.540 million by 3.77 percent. This is a 33.26 percent increase over sales of $33.126 million the same period last year.

LFMD

LifeMD Q1 2024 Adj EPS $0.01 Beats $(0.15) Estimate, Sales $44.144M Beat $42.540M Estimate

Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 30.91 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $15.89 million which beat the analyst consensus estimate of $14.80 million by 7.39 percent. This is a 3.96 percent decrease over sales of $16.55 million the same period last year.

ALEC

Alector Q1 EPS $(0.38) Beats $(0.51) Estimate, Sales $15.89M Beat $14.80M Estimate

Outset Medical Reaffirmed 2024 Revenue Guidance $145M-$153M vs $148.17M Est.

NVEE

NV5 Sees FY24 Revenue $937M-$942M Vs $931M Estimate; Sees Adj. EPS $5.05-$5.11 Vs $5.01 Estimate

Red Violet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDVT#NASDAQ">RDVT</a>) reported quarterly earnings of $0.22 per share. This is a 37.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported $17.51 million in sales this quarter. This is a 19.73 percent increase over sales of $14.63 million the same period last year.

RDVT

Red Violet Q1 Adj $0.22 Up From $0.16 YoY, Sales $17.51M Up From $14.63M YoY

Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) reported quarterly sales of $301.800 million which beat the analyst consensus estimate of $295.743 million by 2.05 percent. This is a 2.93 percent increase over sales of $293.208 million the same period last year.

ACEL

Accel Entertainment Q1 Sales $301.800M Beat $295.743M Estimate

In light of softer than expected net revenue in the&nbsp;first quarter&nbsp;of 2024, the company is adjusting net revenue&nbsp;outlook&nbsp;for the full year 2024. Due to actions being taken to improve Gross Margin, as well as ongoing discipline in managing costs, it is increasing the low end of Adjusted EBITDA&nbsp;outlook&nbsp;for the year.

LVLU

Lulu's Fashion Lounge Revises FY24 Net Revenue Outlook From $350M-$370M To $350M-$360, Est $354.58M

Outlook for 2024
For fiscal year 2024, the Company reaffirmed full year revenue guidance, which is expected to be in the range of $200 million to $205 million.

Standard BioTools Reaffirms Guidance

Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $12.393 million which missed the analyst consensus estimate of $13.666 million by 9.32 percent. This is a 26.14 percent increase over sales of $9.825 million the same period last year.

Avino Silver & Gold Mines Q1 2024 GAAP EPS $0.02, Inline, Sales $12.393M Miss $13.666M Estimate

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $263.200 million which beat the analyst consensus estimate of $254.825 million by 3.29 percent. This is a 7.12 percent increase over sales of $245.700 million the same period last year.

Phibro Animal Health Q3 2024 Adj EPS $0.31 Beats $0.29 Estimate, Sales $263.200M Beat $254.825M Estimate

BNGO

Bionano Reaffirms FY24 Revenue Guidance $37M-$41M

Sonendo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONX#NYSE">SONX</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.09 by 177.78 percent. This is a 56.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $7.047 million which beat the analyst consensus estimate of $6.300 million by 11.86 percent. This is a 18.79 percent decrease over sales of $8.678 million the same period last year.

SONX

Sonendo Q1 2024 GAAP EPS $(0.07) Misses $0.09 Estimate, Sales $7.047M Beat $6.300M Estimate

MRVI

Maravai LifeSciences Reaffirms 2024 Revenue Guidance; Sees Revenue $265M-$285M

Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) reported quarterly earnings of $0.78 per share.

GLRE

Greenlight Capital Re Q1 2024 GAAP EPS $0.78

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of investors betting against a stock, anticipating its decline.



However, when the price unexpectedly jumps, short sellers rush to cover their positions to minimize losses, inadvertently driving the price up further. This cycle can intensify as more short sellers buy to close their positions, adding to the upward momentum in the stock&rsquo;s price.&nbsp;



Traders can spot potential short squeezes by monitoring indicators like short interest, which represents the percentage of a stock&rsquo;s shares borrowed by short sellers. A high short interest suggests a stock may be ripe for a squeeze if buying pressure mounts.



Another key metric to watch closely is &ldquo;days to cover,&rdquo; calculating how long it would take for short sellers to cover their positions based on average trading volume. A high &ldquo;days to cover&rdquo; ratio indicates a stock is more susceptible to a short squeeze. Bottom line, understanding these indicators allows traders to anticipate significant price movements.



Let&rsquo;s look at several short-squeeze stocks that could erupt higher in the coming weeks and months.&nbsp;



<h2>Prime Medicine (PRME)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/prme.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/prme-300x169.png" alt="PRME Short-Squeeze Stocks"></a>Prime Medicine Inc. (NASDAQ:<a href="https://investorplace.com/stock-quotes/prme-stock-quote/">PRME</a>) is a biotechnology company pioneering the development of a new class of genetic medicine based on its proprietary Prime Editing technology. The stock&rsquo;s <a href="https://www.marketwatch.com/tools/screener/short-interest" target="_blank">short interest ratio</a> stands at nearly 34%.



This biotech company seeks to enable precise and permanent gene editing capabilities. It can potentially address genetic diseases at their source by directly repairing mutations. PRME&rsquo;s early stage product pipeline focuses on various genetic disorders with the goal of achieving transformative therapeutic outcomes.



Recently, Prime Medicine <a href="https://seekingalpha.com/news/4067423-prime-medicine-down-5-prices-140m-stock-offering">announced the pricing</a> of a significantly upsized public offering, involving approximately 19.2 million shares at a price of $6.25 each. Furthermore, to accommodate certain investors, pre-funded warrants for nearly 3.2 million shares are being offered at the same price per pre-funded warrant. As expected, the company&rsquo;s stock fell.



Also, the company granted underwriters a 30-day option to purchase up to an additional 3.36 million shares, potentially increasing the offering&rsquo;s size. Prime Medicine anticipates gross proceeds of approximately $140 million from this offering, before accounting for underwriting discounts, commissions, and other offering expenses.&nbsp;



This financial move aims to bolster the company&rsquo;s capital, supporting its innovative endeavors in gene editing technology and the development of genetic medicines. In case Prime Medicine finds success as it moves to bolster its liquidity, shares &ndash; which are down 40% over the last 52 weeks &ndash; could erupt higher.&nbsp;



<h2>iRobot (IRBT)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/irobot.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/irobot-300x169.png" alt="IRBT short-squeeze stocks"></a>iRobot Corporation (NASDAQ:<a href="https://investorplace.com/stock-quotes/irbt-stock-quote/">IRBT</a>) specializes in designing and manufacturing consumer robots. The company is known for its Roomba vacuum cleaning robots, Braava floor mopping robots, and other home automation products. The company&rsquo;s goal is to automate routine cleaning tasks, improving efficiency and convenience for users.&nbsp;



The <a href="https://tokenist.com/irobot-tumbles-after-amazon-deal-termination-layoffs-and-ceo-exit-announced/" target="_blank">company&rsquo;s stock collapsed recently</a> after Amazon (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) was forced to abandon the deal to acquire iRobot due to regulatory hurdles in the European Union. Concurrently, iRobot announced a significant workforce reduction. They laid off approximately 350 employees, or 31% of its staff, as part of a broader restructuring effort.&nbsp;



The restructuring includes the departure of iRobot&rsquo;s co-founder and CEO, Colin Angle. In response to the current challenges, iRobot is scaling back its product development. It will focus on its core floor-cleaning technologies while exiting less profitable markets.&nbsp;



This is a key factor why short-sellers were aggressively shorting IRBT stock, which is down as much as 72% year to date (YTD). The aborted deal with Amazon triggers a $94 million termination fee, aiding iRobot in addressing a substantial part of its $200 million loan.



Further, iRobot remains an innovative company that will likely recover from this blow. In essence, the abandoned Amazon deal makes IRBT more streamlined and efficient, creating it as a bigger M&amp;A target. Short interest ratio stands at more than 33%, making iRobot one of the potential short-squeeze stocks candidates.&nbsp;



<h2>Symbotic (SYM)&nbsp;</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/symbotic.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/symbotic-300x169.png" alt="Symbotic (SYM) Short-Squeeze Stocks	"></a>Symbotic Inc. (NASDAQ:<a href="https://investorplace.com/stock-quotes/sym-stock-quote/">SYM</a>) develops and markets agricultural technologies designed to enhance crop yield and resilience. At the same time, they minimize environmental impact. Its product portfolio includes biofertilizers, biostimulants, and integrated pest management solutions. The company aims to support sustainable farming practices.



In a move to boost its finances, <a href="https://www.symbotic.com/about/news-events/news/symbotic-inc-announces-primary-and-secondary-offering-of-class-a-common-stock/" target="_blank">Symbotic announced an offering</a> of 5 million Class A shares directly by the company. Additionally offered were 5 million Class A shares by shareholder Richard B. Cohen, with Goldman Sachs managing the pricing.&nbsp;



The proceeds from Symbotic&rsquo;s share offering are designated for general corporate purposes. This offering is positioned at a 0.95% discount to the stock&rsquo;s last closing price, causing shares to modestly drop in the aftermath of the announcement. Following the offering, Symbotic will have 89.1 million shares outstanding, with a public float of 15.7 million shares as of February 5th.&nbsp;



Shares fell sharply in February after the company&rsquo;s management implied in the most recent earnings report a slower FY24 profit growth. Still, the management reiterated its focus on product quality and high customer satisfaction. Bottom line, the company reiterated its long-term margin targets.&nbsp;



Therefore, Symbotic remains well-positioned in the long-term despite the recent setback. The short interest ratio stands at about 32.6%, positioning SYM to surge in case the near-term visibility improves.&nbsp;



On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://protect-us.mimecast.com/s/XtC3C1wq33iErOvYSGOsXg?domain=investorplace.com/">Publishing Guidelines</a>.
<div>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/short-squeeze-roulette-3-stocks-that-could-leave-bears-begging/">Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report), Alcid...

Analysts' Top Healthcare Picks: Prime Medicine, Inc. (PRME), Alcidion Group Limited (AU:ALC)

Top 10 worst performing Cathie Wood ARKK holdings of 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report), Arvin...

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)

Geulah Livshits, an analyst from Chardan Capital, has initiated a new Buy rating on Prime Medicine, Inc. (PRME). Geulah Livshits has given his Buy ...

Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Prime Medicine, Inc. (PRME – Research Report). The associated price target...

Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!



Moving stocks this morning are a settlement agreement, Elon Musk&rsquo;s trip to China, a delisting update and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Inno (NYSEARCA:<a href="https://investorplace.com/stock-quotes/inno-stock-quote/">INNO</a>) stock is rocketing more than 58% alongside heavy pre-market trading.</li>



<li>Koninklijke Philips (NYSE:<a href="https://investorplace.com/stock-quotes/phg-stock-quote/">PHG</a>) shares are soaring over 42% after <a href="https://www.cnbc.com/2024/04/29/philips-shares-rocket-33percent-as-firm-settles-us-respiratory-device-case.html">reaching a recall settlement</a>.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) stock is surging more than 22% without any clear news this morning.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are gaining over 19% with strong early morning trading.</li>



<li>Prime Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/prme-stock-quote/">PRME</a>) stock is rising more than 19% despite a lack of news today.</li>



<li>GraniteShares 2x Long TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslr-stock-quote/">TSLR</a>) shares are increasing over 19% after <a href="https://www.bloomberg.com/news/articles/2024-04-29/tesla-clears-key-china-fsd-hurdle-with-baidu-mapping-deal">Elon Musk left China</a> with backing for Tesla&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) self-driving software.</li>



<li>Direxion Daily TSLA Bull 2X Shares (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsll-stock-quote/">TSLL</a>) stock is also heading more than 17% higher alongside the China news.</li>



<li>T-REX 2X Long Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslt-stock-quote/">TSLT</a>) shares are likewise climbing over 17% with the China visit.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is jumping more than 16% on Monday morning.</li>



<li>GlucoTrack (NASDAQ:<a href="https://investorplace.com/stock-quotes/gctk-stock-quote/">GCTK</a>) shares are up close to 16% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Bakkt (NYSE:<a href="https://investorplace.com/stock-quotes/bkkt-stock-quote/">BKKT</a>) stock is crashing over 92% following a <a href="https://www.nasdaq.com/press-release/bakkt-announces-reverse-stock-split-2024-04-23">reverse stock split on Friday</a>.</li>



<li>Marex (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrx-stock-quote/">MRX</a>) shares are plummeting 60% following its <a href="https://www.marex.com/news/2024/04/marex-group-plc-announces-pricing-of-initial-public-offering/">initial public offering (IPO)</a>.</li>



<li>Clever Leaves (NASDAQ:<a href="https://investorplace.com/stock-quotes/clvr-stock-quote/">CLVR</a>) stock is diving more than 58% on <a href="https://www.nasdaq.com/press-release/clever-leaves-announces-voluntary-delisting-and-sec-deregistration-2024-04-26">voluntary delisting plans</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) shares are taking an over 54% beating on a <a href="https://www.nasdaq.com/press-release/addex-provides-update-on-adx71149-phase-2-epilepsy-study-2024-04-29-0">Phase 2 clinical trial update</a>.</li>



<li>GraniteShares 2x Short TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsdd-stock-quote/">TSDD</a>) stock is tumbling more than 18% with Tesla&rsquo;s recent rally.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares are sliding over 17% on Monday morning.</li>



<li>T-Rex 2X Inverse Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslz-stock-quote/">TSLZ</a>) stock is dropping more than 17% alongside Tesla&rsquo;s gains.</li>



<li>Boqii (NYSEMKT:<a href="https://investorplace.com/stock-quotes/bq-stock-quote/">BQ</a>) shares are falling over 16% without any apparent news this morning.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% after a Friday rally.</li>



<li>Nature Wood (NASDAQ:<a href="https://investorplace.com/stock-quotes/nwgl-stock-quote/">NWGL</a>) shares close out our pre-market stock movers down over 14 with no clear news to report.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

FDA clears Prime Medicine to begin gene therapy clinical testing

Jefferies analyst Maury Raycroft assigned a Buy rating to Prime Medicine, Inc. (PRME – Research Report) today and set a price target of $15.00. The...

Jefferies Issues a Buy Rating on Prime Medicine, Inc. (PRME)

AKAN

AMZN

ARKK

ARVN

BKKT

CMPS

COIN

GCTK

INNO

IRBT

TDOC

TSDD

TSLL

TSLR

TSLT

TSLZ

TWOU

VERV

VRDN

XTLB

Press Releases

Prime Medicine Announces Proposed Public Offering of Common Stock

IPOs

Prime Medicine Announces Pricing of Upsized Public Offering

Financing

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Health Care

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Small Cap

Opinion

Thinking about buying stock in KULR Technology, Prime Medicine, Solidion Technology, Sharp Corp, or Fisker?

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Analyst Ratings

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prime Medicine Stock (NASDAQ:PRME), Short Interest Report

People Also Watch